Stay updated with the latest news from AbbVie
We are very excited to enter into this new era for AbbVie. The acquisition of Allergan marks a crucial step forward in our mission: to make a remarkable impact on patients’ lives.
In ANZ, today, our medicines help more than 40,000 people and we are making significant advancements with a robust pipeline of potential new medicines.
The acquisition enhances our ability to invest in promising and innovative science over the long-term in several areas of medical need.
As an expanded company, we will be able to help more patients. We will continue pushing scientific boundaries, investing in research and development for critical areas of unmet need. While we have significantly grown our pipeline since launching in 2013, we are now poised to grow our long-term research efforts and innovate to accelerate the development process.
We are a passionate, diverse and inclusive organisation with a culture that supports the best ideas, wherever they originate. We bring people together because we know that collaboration is the key to breaking barriers and exploring new frontiers in science.
The Medical Aesthetics business Allergan has built is highly respected and has delivered world-renowned brands for the customers and patients they serve. This will continue to be an area of focus and investment now as Allergan Aesthetics, an AbbVie company.
Allergan’s leadership in Eye Care is built on 70 years of innovation, focussing on the development and launch of eye care products for conditions impacting both the front and back of the eye, including glaucoma, artificial tears and retina.
Our areas of focus
AbbVie is committed to changing the lives of patients by developing innovative treatments. For nearly two decades, we have been pioneers in the field of immunology, pursuing breakthrough science and using the highest-quality manufacturing to deliver medicines for patients who need them most. Building on our strong leadership in this area, we have forged ahead with a portfolio of new treatments, which are in varying stages of regulatory review or approval around the world.
Our goal is to transform the way cancer is treated. We have multiple approved medicines and are continuing to focus on achieving better, long-term control of blood cancers, including chronic lymphocytic leukaemia, non-Hodgkin’s lymphoma, acute myeloid leukaemia and multiple myeloma. We are also investing in groundbreaking technology and partnering with leaders across the field to identify and advance promising therapies for solid tumors.
Allergan’s portfolio includes some of the worlds most renowned brands of aesthetics products. Allergan continues to develop new therapies and devices that safely and effectively address skin conditions, fat reduction, facial lines and facial volume. As an AbbVie company, Allergan Aesthetics will continue its differentiating strong customer service programs and grow and expand its leadership position.
Our commitment to addressing the needs of people living with neurodegenerative disease is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, caregivers and clinicians. AbbVie’s neuroscience portfolio consists of approved therapies for advanced Parkinson’s disease and a robust pipeline in other neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. Through the acquisition of Allergan, we also add several medicines to our portfolio for bipolar disorder and schizophrenia and to treat chronic migraines, overactive bladder and other conditions of the central nervous system.
As part of AbbVie, Allergan’s mission in eye care remains to protect and preserve vision for a better quality of life for the millions of people who experience vision loss every year. Allergan’s eye care medicines treat glaucoma, ocular hypertension and other conditions. Scientists are currently pursuing promising avenues of research to treat retina-related diseases such as macular oedema, diabetic macular oedema and age-related macular degeneration.
AbbVie is leading global efforts aimed at achieving the World Health Organization’s (WHO) goal of eliminating hepatitis C virus (HCV) by 2030. We have launched innovative treatment options, with the goal of offering more people a path to a cure because every patient cured accelerates the path to elimination. We are also working hard to help forge the way to HCV elimination by fostering transformative partnerships with the HCV community, removing barriers to care to find sustainable solutions that allow more patients to be screened and treated.
Other specialty areas
In addition to our key therapeutic areas of focus, we use our scientific expertise to discover and develop medicines for diseases where patients still have limited treatment options including endometriosis, uterine fibroids, cystic fibrosis, reproductive health, acute migraine, ulcerative colitis, overactive bladder and irritable bowel syndrome.
Last updated May 2020